Norges Bank’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Norges Bank’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-29,650	Closed	-$290K	–	2182
2016 Q3	$290K	Sell	29,650 -17,337	-37%	-$189K	﹤0.01%	2130
2016 Q2	$614K	Sell	46,987 -23,900	-34%	-$313K	﹤0.01%	2113
2016 Q1	$780K	Hold	70,887	–	–	﹤0.01%	2095
2015 Q4	$652K	Hold	70,887	–	–	﹤0.01%	2152
2015 Q3	$492K	Sell	70,887 -200,310	-74%	-$1.72M	﹤0.01%	2191
2015 Q2	$2.66M	Hold	271,197	–	–	﹤0.01%	2005
2015 Q1	$2.4M	Hold	271,197	–	–	﹤0.01%	2042
2014 Q4	$2.38M	Buy	271,197 +163,206	+151%	+$1.32M	﹤0.01%	2067
2014 Q3	$744K	Sell	107,991 -107,991	-50%	-$647K	﹤0.01%	2226
2014 Q2	$1.14M	Buy	215,982 +107,991	+100%	+$525K	﹤0.01%	2165
2014 Q1	$491K	Hold	107,991	–	–	﹤0.01%	2087
2013 Q4	$544K	Buy	+107,991	New	+$520K	﹤0.01%	2064

Other funds holding SCLN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Norges Bank's SCLN Position: Q4 2016 in Review

Norges Bank sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 29,650 shares — an estimated $290K sold.

Norges Bank first reported a position in SCLN in Q4 2013 and held it in 12 quarters. The position peaked at $2.66M in Q2 2015. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

Norges Bank reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Norges Bank sold 29,650 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $290K.
Norges Bank first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 12 quarters.
Norges Bank's Sciclone Pharmaceuticals Inc position peaked at $2.66M in Q2 2015.
153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Norges Bank's 13F filing for Q4 2016, filed 9 Feb 2017.